Shares of Allogene Therapeutics, Inc. (ALLO) are up over 50% at $4.32 today, following data from the planned interim futility analysis of its pivotal, randomized Phase 2 ALPHA3 trial in first-line (1L) consolidation large B-cell lymphoma (LBCL).
ALPHA3 is a pivotal Phase 2 study evaluating first-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma who have minimal residual disease after responding to standard therapy.
According to the trial results, Cemacabtagene ansegedleucel (cema-cel) showed strong activity in first-line consolidation for large B-cell lymphoma, with 58.3% of patients achieving minimal residual disease (MRD) clearance compared to 16.7% in the observation group.
Enrollment in the phase 2 ALPHA3 trial is expected to be completed by the end of 2027, with an interim event-free survival (EFS) analysis planned for mid-2027 and the primary EFS readout expected in mid-2028.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.